Clinical trials
Hypertrophic Cardiomyopathy clinical trials
Below are recruiting hypertrophic cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03479580Recruiting
Registry for coronary and small-vessel heart disease in cardiomyopathy
This study enrolls people with certain types of heart muscle diseases to learn how blocked heart arteries and tiny blood vessels affect symptoms and outcomes. It may help researchers better understand these conditions and improve future care.
La TroncheAges 18–100 - NCT06683872Enrolling by invitation
CT heart modeling for hypertrophic obstructive cardiomyopathy
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
Hangzhou, ZhejiangAges 18–70 - NCT07103655Enrolling by invitationPhase 4
Mavacamten for mid-to-apical obstruction in HCM
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
Hangzhou, ZhejiangAges 18–75 - NCT07359690Recruiting
Study of Heart Muscle Biopsies
This study collects samples of heart muscle tissue (biopsy) to better understand heart conditions. It is for people who already need this biopsy for their healthcare.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07557498Recruiting
Mavacamten Outcomes and Experiences in Heart Muscle Disease
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Bollington, MacclesfieldAges 18 years+ - NCT02804269Recruiting
Ages 16 to 90 for heart disease information collection
This is a repository program that collects health and imaging-related information to better understand heart (cardiovascular) health and disease. You may be able to join if you are in the age range and share your data for research use.
Singapore, SingaporeAges 16–90 - NCT07354646Recruiting
Understanding heart disease with T1 mapping MRI
This study uses a special type of MRI (T1 mapping) to better understand different heart conditions. It may help doctors improve diagnosis and treatment by looking at detailed images of your heart muscle.
Beijing, Beijing MunicipalityAges Any age - NCT06935253Recruiting
AI to Improve Cardiology Care
This trial tests whether large language models (a type of AI that understands human language) can help cardiologists give better care. If you are a qualified cardiologist who currently treats patients, you may be eligible.
Palo Alto, CaliforniaAges 18 years+ - NCT07344480Recruiting
Study on heart disease in children with RASopathy
This study looks at medical records of children with a genetic condition called RASopathy who developed thickened heart muscle and needed hospital care for heart failure in their first six months of life. The goal is to understand how the heart condition progresses over time.
MünchenAges Any age - NCT04189822Enrolling by invitation
Heart rhythm genetic registry and blood sample bio bank
This study is building a Canadian database and tissue/blood bank for people and families with inherited heart rhythm conditions (and some inherited heart muscle diseases). It collects consented health and genetic information to help researchers better understand who is at risk and how these conditions work.
Vancouver, British ColumbiaAges Any age - NCT07541833Recruiting
Mavacamten Treatment Patterns in Obstructive Heart Thickening
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Minato-ku, TokyoAges 18 years+ - NCT06409585Recruiting
Heart muscle disease imaging study for scarring
This study uses advanced imaging (PET/MR or PET/CT) to look at scarring (fibrosis) in the heart muscle. It is for people with various heart muscle diseases, including heart failure with preserved pumping, thickened heart muscle, high blood pressure-related heart damage, heart inflammation, and others.
Edinburgh, ScotlandAges 30–90 - NCT07054073Recruiting
HCMR Re-Imaging: MRI follow-up for HCM patients
This study uses MRI scans to re-examine people with hypertrophic cardiomyopathy (a thickening of the heart muscle) who were part of the original HCMR study. It compares different types of HCM to learn more over time.
Boston, MassachusettsAges 18–65 - NCT05081115Recruiting
Stress echo imaging for people with heart valve or muscle issues
This trial studies a stress echocardiogram (an ultrasound of the heart during stress) to better understand and improve future heart imaging. It may help by comparing how well the test works for different heart conditions.
BeneventoAges 18–75 - NCT03362164Recruiting
Studying heart involvement in people with Fabry disease
This study looks at how the heart is affected in adults with Fabry disease. It may help doctors better understand heart-related changes in order to guide care.
Würzburg, BavariaAges 18 years+ - NCT07867288RecruitingPhase 1
Study of an investigational drug for non-obstructive hypertrophic cardiomyopathy
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
Kansas City, MissouriAges 18–70 - NCT06555237RecruitingPhase 2
MEK inhibitors for heart thickening in RASopathies
This trial tests a targeted drug (MEK inhibitor) to treat thickened heart muscle caused by a group of genetic conditions called RASopathies. It may help improve heart function in people with hypertrophic cardiomyopathy.
WarsawAges 1 day–18 years - NCT07738107RecruitingPhase 1/Phase 2
Study of ATR 1072 for PRKAG2 syndrome
This trial tests a new medicine called ATR 1072 for people with PRKAG2 syndrome, a genetic heart condition. It aims to see if the drug is safe and can help manage symptoms.
Kansas City, MissouriAges 18–65 - NCT06023186Recruiting
Effect of mavacamten on heart blood flow in HCM
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Charlottesville, VirginiaAges 18–85 - NCT06551129Recruiting
Camzyos treatment in real life: patient experiences
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
Boston, MassachusettsAges 18 years+ - NCT07464132RecruitingPhase 1/Phase 2
New PET scan for detecting certain diseases
This trial uses a special PET scan tracer to see if it can help find and monitor diseases linked to a protein called FAP. It is for both cancer patients needing a biopsy and healthy volunteers.
Beijing, Beijing MunicipalityAges 18–85 - NCT07454135Recruiting
Studying heart muscle disease and atrial fibrillation
This trial looks at how the heart's electrical signals work in people with hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened) who also have atrial fibrillation (a type of irregular heartbeat). The goal is to understand these signals better during a planned ablation procedure, which is a treatment to fix the irregular rhythm.
LondonAges 18–80 - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT05939700Recruiting
Watching infants after mavacamten use in pregnancy
This study follows people who took mavacamten during pregnancy or breastfeeding to better understand infant outcomes. It may help doctors and families know what to expect and improve safety guidance.
Wilmington, North CarolinaAges 15 years+
Hear when a new Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hypertrophic cardiomyopathy?
- Yes. Clin2 currently lists 78 recruiting hypertrophic cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hypertrophic cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hypertrophic cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.